Daily CBD treatment eliminated or reversed the direction of expression in more than 75% of over 1,000 molecular markers associated with Alzheimer's disease onset in a mouse model.
Alzheimer's researchers, neuroscientists, anyone interested in CBD's neuroprotective potential
More than 75% of 1,000+ Alzheimer's markers were reversed by CBD treatment in mice
What the researchers found
RNA sequencing identified over 1,000 differentially expressed markers of Alzheimer's disease onset in mice. CBD treatment (80-100 mg/kg/day for 2 months) either eliminated or reversed the expression direction of more than 75% of these markers, spanning pathways including synaptic development, neurovascular interactions, mitochondrial function, and immunity.
Why it matters
Most Alzheimer's treatments target one or two pathways. This study suggests CBD simultaneously affects dozens of pathways involved in disease onset, from inflammation and oxidative stress to synaptic plasticity and lipid metabolism, a breadth of action that single-target drugs cannot match.
The numbers in context
Over 1,000 differentially expressed markers of AD onset identified; more than 75% eliminated or reversed by CBD; 80-100 mg/kg/day dose; treatment from 4.5 to 6.5 months of age; pathways affected include Foxp2 (synaptic), Smad9/Angptl6 (neurovascular), Gria4/Chrna2 (receptors), Ndufa7/Cox7a2 (mitochondrial)
How the study worked
Male 3xTg-AD mice and wild-type controls received daily dietary CBD (80-100 mg/kg/day) from 4.5 to 6.5 months of age. Researchers used RNA sequencing on blood and brain samples, metabolomics on brain regions, and behavioral assessments.
What this study cannot tell us
Mouse model (3xTg-AD) does not fully replicate human Alzheimer's, male mice only, high CBD dose relative to human equivalents, treatment started before full disease development, no long-term follow-up beyond 2 months
How to read the evidence
Single animal study in one transgenic mouse model; impressive molecular breadth but male mice only and no human data
When this study was published
Published 2025
The bigger picture
Alzheimer's disease involves a cascade of interconnected molecular failures. The finding that CBD addresses more than 75% of these simultaneously in mice is remarkable, though the gap between mouse models and human Alzheimer's disease remains enormous.
Questions still open
- Would CBD show similar molecular breadth in human Alzheimer's patients? Does the timing of CBD treatment (early vs late disease) matter? What happens when treatment stops?
Common questions
Can CBD treat Alzheimer's disease?
How many Alzheimer's-related changes did CBD affect?
Read the original research
Molecular pathogenesis of Alzheimer's disease onset in a mouse model: effects of cannabidiol treatment.
Frontiers in neuroscience, 19, 1667585
Citation
Bishara, Mary A; Chum, Phoebe P; Miot, Fritz E L; Hooda, Ankita; Hartman, Richard E; Behringer, Erik J. (2025). Molecular pathogenesis of Alzheimer's disease onset in a mouse model: effects of cannabidiol treatment.. Frontiers in neuroscience, 19, 1667585. https://doi.org/10.3389/fnins.2025.1667585
Explore the wider topic
- CBD Oil Quality Guide: How to Avoid Snake Oil
- Anxiety After Quitting Weed: When to Consider Medication
- Cannabis for Chemotherapy Nausea: What the Evidence Actually Shows
- Cannabis for Chronic Pain: What the Research Actually Supports
- Cannabis and Epilepsy: The Epidiolex Story and What It Means
- Does CBD Actually Work for Anxiety? What the Evidence Shows
- Does CBD Help with Weed Withdrawal? What Studies Show
- CBD vs THC: The Differences That Actually Matter
- The Proven Medical Benefits of Cannabis: What Research Supports
- Quitting Weed Before Surgery
- Weed and Medications: What Changes When You Quit
- Quitting Weed During Pregnancy: What You Need to Know
- Quitting Weed While Pregnant: What You Need to Know
- Cannabis and Older Adults: Risks Seniors Should Know
- Cannabis and Breastfeeding: THC in Breast Milk